Valuation: Profound Medical Corp

Market Cap 380M 267M 234M 216M 200M 25.5B 385M 2.58B 1B 12.52B 1B 982M 43.4B P/E 2026 *
-9.03x
P/E 2027 * -10.1x
Enterprise Value 380M 267M 234M 216M 200M 25.5B 385M 2.58B 1B 12.52B 1B 982M 43.4B EV / Sales 2026 *
10.6x
EV / Sales 2027 * 6.26x
Free-Float
95.93%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 71 15/08/2016
President 44 07/11/2024
Director of Finance/CFO 58 03/03/2022
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 14/06/2018
Director/Board Member 79 14/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%+2.94%+23.26%+0.46% 192B
+1.36%+10.30%-17.97%+32.40% 153B
+0.51%+1.98%-2.69%-16.66% 137B
+2.65%+7.73%-55.72%-12.07% 66.29B
-0.35%+5.28%+24.19%+5.52% 54.8B
+1.36%+3.16%-24.29%-28.84% 44.44B
-0.13%+0.40%+8.60%+42.54% 37.2B
+0.35%-2.03%+9.12%+11.22% 36.89B
-0.35%+11.38%-15.35%+0.58% 31.5B
Average +0.69%+3.01%-5.65%+3.91% 83.76B
Weighted average by Cap. +0.76%+3.29%-2.55%+3.99%

Financials

2026 *2027 *
Net sales 35.76M 25.15M 22.03M 20.29M 18.83M 2.4B 36.24M 243M 94.51M 1.18B 94.45M 92.37M 4.08B 60.68M 42.68M 37.38M 34.43M 31.95M 4.07B 61.5M 412M 160M 2B 160M 157M 6.93B
Net income -43.31M -30.46M -26.68M -24.57M -22.81M -2.91B -43.89M -294M -114M -1.43B -114M -112M -4.94B -40.7M -28.63M -25.07M -23.09M -21.44M -2.73B -41.25M -276M -108M -1.34B -108M -105M -4.65B
Net Debt - -
Logo Profound Medical Corp
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-